The Pharmacy Times® Diabetes Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of chronic diseases that result in high blood glucose.
August 21st 2025
Simplifying complex information through illustrations and storytelling helps patients feel that managing their condition is achievable.
Empagliflozin Slows Renal Disease Progression in Type 2 Diabetes
June 23rd 2016New data from the EMPA-REG OUTCOME trial showed the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) significantly reduced the incidence of worsening kidney disease in type 2 diabetes patients.
Read More